-
C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory studyBuzzetti, Raffaella ...OBJECTIVE: To investigate whether lower risk HLA class II genotypes would influence the efficacy of DiaPep277 therapy in protecting beta-cell function evaluated by C-peptide secretion in recent-onset ... type 1 diabetic subjects. RESEARCH DESIGN AND METHODS: Data were collected from type 1 diabetic subjectsenrolled in multicenter phase II studies with a randomized, double-blind, and placebo-controlled design in whom fasting and stimulated C-peptide levels were measured. HLA genotypes were classified in high, moderate, and low risk categories. RESULTS: A total of 146 subjects (aged 4.3 to 58.5 years) were enrolled, including 76 children (<18 years old) and 70 adults. At baseline, there was a significant increase in fasting, maximal, andarea under the curve (AUC) C-peptide from high to moderate and low risk HLAgenotypes in adults (P for trend <0.04) but not in children. Children showed a decrease of the three parameters over time regardless of therapy and HLA genotype. DiaPep277-treated adults with low risk genotype had significantly higher maximal and AUC C-peptide versus placebo at 12 months (0.04 +/- 0.07 vs. -0.28 +/- 0.09 nmol/L, P < 0.01, and 0.53 +/- 1.3 vs. -4.59+/- 1.5 nmol/L, P < 0.05, respectively). In the moderate risk genotype group, Deltamaximal and AUC C-peptide values were significantly higher in DiaPep277-treated versus placebo-treated patients (P < 0.01 and P < 0.05, respectively). CONCLUSIONS: This exploratory study demonstrates that type 1 diabetic adults with low and moderate risk HLA genotypes benefit the most fromintervention with DiaPep277; the only subgroup with an increase of C-peptide at 12 months after diagnosis was the low risk DiaPep277-treated subgroup.Vir: Diabetes. - ISSN 0012-1797 (Vol. 60, no. 11, 2011, str. 3067-3072)Vrsta gradiva - članek, sestavni delLeto - 2011Jezik - angleškiCOBISS.SI-ID - 29623513
Avtor
Buzzetti, Raffaella |
Cernea, Simona |
Petrone, Antonio |
Capizzi, Marco |
Spoletini, Marialuisa |
Zampetti, Simona |
Guglielmi, Chiara |
Venditti, Chiara |
Pozzilli, Paolo |
Battelino, Tadej
Teme
Genes, MHC Class II |
Diabetes Mellitus, Insulin-Dependent |
C-Peptide |
Immunotherapy |
Genotype |
Autoantigens |
Randomized Controlled Trials |
Multicenter Studies |
Age Factors |
Chaperonin 60 |
Therapeutic Use |
Double-Blind Method |
Hypoglycemic Agents |
Therapeutic Use |
Kinetics |
Peptide Fragments |
Therapeutic Use |
Imunoterapija |
Sladkorna bolezen inzulin-odvisna |
Genotip |
Geni MHC razred II |
C-peptid |
Haperonin 60 |
Dvojnoslepa metoda |
Hipoglikemiki |
Naključno kontrolirane, klinične preiskave |
Avtoantigeni |
Kinetika |
Policentrične študije |
Starostni faktorji |
Peptidni deli
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Buzzetti, Raffaella | ![]() |
Cernea, Simona | ![]() |
Petrone, Antonio | ![]() |
Capizzi, Marco | ![]() |
Spoletini, Marialuisa | ![]() |
Zampetti, Simona | ![]() |
Guglielmi, Chiara | ![]() |
Venditti, Chiara | ![]() |
Pozzilli, Paolo | ![]() |
Battelino, Tadej | 13023 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.